Applied Genetic Technologies Corporation announced the appointment of Matthew Feinsod, M.D. as Interim Chief Medical Officer. Dr. Feinsod, who previously served as AGTC Product Development Officer, will replace Michael Goldstein, M.D. who is leaving to pursue other career opportunities. Dr. Feinsod, a board-certified ophthalmologist, joined AGTC in July 2014. In his previous positions he played key roles in developing and implementing clinical and regulatory strategy, due diligence and licensing. He holds multiple patents in the field of ophthalmology, and has been a founder in several companies, including Imagen Biotech, a venture-backed company dedicated to developing breakthrough ophthalmology treatments for sight-threatening diseases with high unmet medical needs. Prior to Imagen, Dr. Feinsod was Senior Vice President of Strategy and Product Development at Eyetech Pharmaceuticals where he spent five years in a variety of functions helping to develop and launch Macugen.